Research Analysts Set Expectations for AMLX FY2029 Earnings

Amylyx Pharmaceuticals, Inc. (NASDAQ:AMLX) – Research analysts at HC Wainwright cut their FY2029 earnings per share estimates for Amylyx Pharmaceuticals in a research report issued to clients and investors on Friday, August 7th. HC Wainwright analyst A. Fein now expects that the company will earn $1.66 per share for the year, down from their prior forecast of $1.79. HC Wainwright currently has a “Buy” rating and a $34.00 target price on the stock. The consensus estimate for Amylyx Pharmaceuticals’ current full-year earnings is ($1.42) per share. HC Wainwright also issued estimates for Amylyx Pharmaceuticals’ FY2030 earnings at $3.74 EPS.

A number of other research firms have also weighed in on AMLX. Weiss Ratings restated a “sell (d-)” rating on shares of Amylyx Pharmaceuticals in a report on Wednesday, August 5th. Guggenheim boosted their price objective on Amylyx Pharmaceuticals from $30.00 to $40.00 and gave the stock a “buy” rating in a report on Thursday, June 25th. Wall Street Zen downgraded Amylyx Pharmaceuticals from a “hold” rating to a “sell” rating in a research note on Saturday, May 9th. Citigroup raised their target price on Amylyx Pharmaceuticals from $20.00 to $26.00 and gave the company a “buy” rating in a report on Monday, August 3rd. Finally, Mizuho upped their price target on Amylyx Pharmaceuticals from $21.00 to $24.00 and gave the stock an “outperform” rating in a report on Monday, July 20th. One analyst has rated the stock with a Strong Buy rating, eight have issued a Buy rating and one has issued a Sell rating to the company. Based on data from MarketBeat.com, the stock has an average rating of “Moderate Buy” and an average target price of $25.38.

Amylyx Pharmaceuticals Trading Up 4.2%

AMLX opened at $23.63 on Monday. The company’s fifty day moving average price is $17.74 and its two-hundred day moving average price is $15.86. Amylyx Pharmaceuticals has a 1-year low of $7.63 and a 1-year high of $24.60. The company has a market cap of $2.63 billion, a price-to-earnings ratio of -16.52 and a beta of -0.21.

Amylyx Pharmaceuticals (NASDAQ:AMLX) last issued its earnings results on Thursday, August 6th. The company reported ($0.39) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($0.36) by ($0.03).

Institutional Inflows and Outflows

Hedge funds and other institutional investors have recently added to or reduced their stakes in the stock. Vanguard Group Inc. increased its position in Amylyx Pharmaceuticals by 10.1% in the fourth quarter. Vanguard Group Inc. now owns 5,804,912 shares of the company’s stock worth $70,123,000 after buying an additional 531,162 shares during the last quarter. Dimensional Fund Advisors LP raised its stake in shares of Amylyx Pharmaceuticals by 17.1% in the first quarter. Dimensional Fund Advisors LP now owns 903,192 shares of the company’s stock valued at $12,544,000 after buying an additional 131,944 shares during the period. Bank of New York Mellon Corp lifted its position in shares of Amylyx Pharmaceuticals by 15.5% during the 1st quarter. Bank of New York Mellon Corp now owns 251,104 shares of the company’s stock valued at $3,490,000 after buying an additional 33,757 shares during the last quarter. iA Global Asset Management Inc. bought a new position in shares of Amylyx Pharmaceuticals during the 1st quarter worth $4,237,000. Finally, Stempoint Capital LP grew its stake in shares of Amylyx Pharmaceuticals by 18.5% during the 1st quarter. Stempoint Capital LP now owns 669,685 shares of the company’s stock worth $9,309,000 after acquiring an additional 104,545 shares during the period. 95.84% of the stock is currently owned by hedge funds and other institutional investors.

Insiders Place Their Bets

In related news, insider Gina Mazzariello sold 15,000 shares of the stock in a transaction dated Thursday, July 9th. The shares were sold at an average price of $18.32, for a total transaction of $274,800.00. Following the completion of the transaction, the insider owned 194,090 shares in the company, valued at approximately $3,555,728.80. This represents a 7.17% decrease in their ownership of the stock. The transaction was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through this link. Insiders own 10.90% of the company’s stock.

Key Stories Impacting Amylyx Pharmaceuticals

Here are the key news stories impacting Amylyx Pharmaceuticals this week:

• Positive Sentiment: Amylyx was identified by Zacks as one of four biotech companies with major second-half 2026 catalysts. The potential catalysts include regulatory decisions and late-stage clinical-trial readouts, which could provide important updates on the company’s pipeline and support investor optimism. 4 Biotech Stocks With Major Second-Half Pipeline Catalysts This Year
• Positive Sentiment: HC Wainwright maintained a Buy rating and a $34 price target for Amylyx. The target implies further upside from recent trading levels and may have helped reinforce the bullish view among investors. Amylyx Pharmaceuticals Analyst Coverage
• Neutral Sentiment: Reported short interest was listed at zero shares, unchanged from the prior reporting period, with a zero-day days-to-cover ratio. Because the figures appear anomalous, they provide little meaningful information about short-selling pressure or potential short-covering demand.
• Negative Sentiment: HC Wainwright reduced its EPS forecasts across the 2026–2028 period, including estimates of losses of $1.49 per share for fiscal 2026, $1.40 for fiscal 2027, and $1.08 for fiscal 2028. Quarterly loss estimates were also lowered to $0.35 per share for the third quarter of 2026 and $0.37 for the fourth quarter, signaling expectations for continued cash burn and weaker profitability than previously projected. HC Wainwright Amylyx Estimates

About Amylyx Pharmaceuticals

Amylyx Pharmaceuticals, Inc is a biopharmaceutical company dedicated to developing treatments for rare and debilitating neurological diseases. Founded in 2013 and headquartered in Cambridge, Massachusetts, the company focuses on leveraging novel approaches to target cellular pathways implicated in neurodegeneration. Amylyx’s research platform centers on small-molecule therapies designed to protect neurons and support cellular health in patients with conditions that currently have limited or no disease-modifying treatment options.

The company’s lead product, AMX0035, is marketed under the trade name Relyvrio following U.S.